Personalis profit margin PSNL
Gross, operating and net profit as a share of revenue over the last twelve months, from 2018.
- Net margin, 12 months
- n/m
- not a meaningful number
- Peer median
- 10.6%
Personalis' net margin works out at −154% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.
Profit margin over time
GrossOperatingNet
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | n/a | 22.7% |
| FY2024 | −96.1% | −80.7% | 31.7% |
| FY2023 | n/a | n/a | 24.8% |
| FY2022 | n/a | n/a | 20.5% |
| FY2021 | −76.3% | −76.4% | 37.0% |
| FY2020 | −52.5% | −53.6% | 25.6% |
| FY2019 | −38.5% | −34.4% | 33.9% |
| FY2018 | −52.6% | −36.5% | 31.3% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | n/a | n/a | n/a | |
| Q1 FY26 | n/a | n/a | n/a | |
| Q4 FY25 | n/a | n/a | n/a | |
| Q3 FY25 | n/a | n/a | n/a | |
| Q2 FY25 | n/a | n/a | −89.6% | |
| Q1 FY25 | −98.1% | n/a | −78.3% | |
| Q4 FY24 | −96.1% | n/a | −80.7% | |
| Q3 FY24 | n/a | n/a | −84.7% | |
| Q2 FY24 | n/a | n/a | n/a | |
| Q1 FY24 | n/a | n/a | n/a | |
| Q4 FY23 | n/a | n/a | n/a | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Medical - Diagnostics & Research nearest Personalis' size, closest first, today.
| Company | Profit margin |
|---|---|
| PSNLPersonalis | n/m |
| CDNACareDx | 24.2% |
| VCYTVeracyte | 20.4% |
| BLLNBillionToOne | 9.5% |
| NRCNRC Health | 4.2% |
| LNTHLantheus | 17.7% |
| CAICaris Life Sciences | 10.6% |
| BIOBio-Rad Laboratories | 8.6% |
| Peer median | 10.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Personalis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.